Cargando…
A suggested follow-up time for breast cancer patients.
The data for this study, consisting of 300 females treated for breast cancer in 1951-1961, were evaluated in order to ascertain when excess mortality from breast cancer disappears and what would be an appropriate follow-up period for investigational purposes. The clinical stages of the patients were...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001540/ https://www.ncbi.nlm.nih.gov/pubmed/3801277 |
_version_ | 1782135625436102656 |
---|---|
author | Leivonen, M. K. Saario, I. A. Peltokallio, P. Tuominen, L. Kalima, T. V. |
author_facet | Leivonen, M. K. Saario, I. A. Peltokallio, P. Tuominen, L. Kalima, T. V. |
author_sort | Leivonen, M. K. |
collection | PubMed |
description | The data for this study, consisting of 300 females treated for breast cancer in 1951-1961, were evaluated in order to ascertain when excess mortality from breast cancer disappears and what would be an appropriate follow-up period for investigational purposes. The clinical stages of the patients were classified as follows: 23.3%, stage I; 49%, stage II; 20.3%, stage III and 7.3%, stage IV. Halsted's radical mastectomy was performed in 79.7% of the cases. Every patient was given radiotherapy. Two hundred and ninety-eight patients could be followed until death or up to the present. Forty-five patients (16%) were still alive. The survival rate over a 20-year period for the various stages was as follows: stage I, 46.1%; stage II, 22.7% and stage III, 10.9%. Only 26% of the patients with stage I died of breast cancer, while the respective figures for stage II were 57% and stage III, 70%. The death rate from the cancer diminished with time in every stage especially 10 years after primary treatment. After this the observed survival rate curves were almost parallel with the expected curves. Our data show that for follow-up studies a 5-year follow-up is good and a 10-year follow-up is very good to show the trend in the treatment of breast cancer. |
format | Text |
id | pubmed-2001540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1986 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20015402009-09-10 A suggested follow-up time for breast cancer patients. Leivonen, M. K. Saario, I. A. Peltokallio, P. Tuominen, L. Kalima, T. V. Br J Cancer Research Article The data for this study, consisting of 300 females treated for breast cancer in 1951-1961, were evaluated in order to ascertain when excess mortality from breast cancer disappears and what would be an appropriate follow-up period for investigational purposes. The clinical stages of the patients were classified as follows: 23.3%, stage I; 49%, stage II; 20.3%, stage III and 7.3%, stage IV. Halsted's radical mastectomy was performed in 79.7% of the cases. Every patient was given radiotherapy. Two hundred and ninety-eight patients could be followed until death or up to the present. Forty-five patients (16%) were still alive. The survival rate over a 20-year period for the various stages was as follows: stage I, 46.1%; stage II, 22.7% and stage III, 10.9%. Only 26% of the patients with stage I died of breast cancer, while the respective figures for stage II were 57% and stage III, 70%. The death rate from the cancer diminished with time in every stage especially 10 years after primary treatment. After this the observed survival rate curves were almost parallel with the expected curves. Our data show that for follow-up studies a 5-year follow-up is good and a 10-year follow-up is very good to show the trend in the treatment of breast cancer. Nature Publishing Group 1986-11 /pmc/articles/PMC2001540/ /pubmed/3801277 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Leivonen, M. K. Saario, I. A. Peltokallio, P. Tuominen, L. Kalima, T. V. A suggested follow-up time for breast cancer patients. |
title | A suggested follow-up time for breast cancer patients. |
title_full | A suggested follow-up time for breast cancer patients. |
title_fullStr | A suggested follow-up time for breast cancer patients. |
title_full_unstemmed | A suggested follow-up time for breast cancer patients. |
title_short | A suggested follow-up time for breast cancer patients. |
title_sort | suggested follow-up time for breast cancer patients. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001540/ https://www.ncbi.nlm.nih.gov/pubmed/3801277 |
work_keys_str_mv | AT leivonenmk asuggestedfollowuptimeforbreastcancerpatients AT saarioia asuggestedfollowuptimeforbreastcancerpatients AT peltokalliop asuggestedfollowuptimeforbreastcancerpatients AT tuominenl asuggestedfollowuptimeforbreastcancerpatients AT kalimatv asuggestedfollowuptimeforbreastcancerpatients AT leivonenmk suggestedfollowuptimeforbreastcancerpatients AT saarioia suggestedfollowuptimeforbreastcancerpatients AT peltokalliop suggestedfollowuptimeforbreastcancerpatients AT tuominenl suggestedfollowuptimeforbreastcancerpatients AT kalimatv suggestedfollowuptimeforbreastcancerpatients |